Movement Alert｜SELLAS Life Sciences Group Inc. Falls 8.06% in Regular Trading, Trading at $11.89

Market Focus07-23

On July 23, SELLAS Life Sciences Group Inc. fell 8.06% in regular trading, trading at $11.89 USD/share, with Turnover of $44.64 million.

Within the Biotechnology sector where SELLAS Life Sciences Group Inc. belongs, among individual stocks, Arrowhead Pharmaceuticals up 23.54%, Lakewood-Amedex Biotherapeutics up 70.7%, AbbVie down 0.8%, Ionis Pharmaceuticals down 0.42%, Regeneron Pharmaceuticals down 3.14%.

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for various cancer indications. Its lead product candidate is galinpepimut-S (GPS), currently in a pivotal Phase 3 REGAL trial for the treatment of acute myeloid leukemia, with final analysis approaching upon reaching 80 events.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1110506485?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 01:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110506485","market":"us","top_or_hot":-1,"title":"Movement Alert｜SELLAS Life Sciences Group Inc. Falls 8.06% in Regular Trading, Trading at $11.89","media":"Market Focus","content":"<p><p>On July 23, SELLAS Life Sciences Group Inc. fell 8.06% in regular trading, trading at $11.89 USD/share, with Turnover of $44.64 million.</p><p>Within the Biotechnology sector where SELLAS Life Sciences Group Inc. belongs, among individual stocks, Arrowhead Pharmaceuticals up 23.54%, Lakewood-Amedex Biotherapeutics up 70.7%, AbbVie down 0.8%, Ionis Pharmaceuticals down 0.42%, Regeneron Pharmaceuticals down 3.14%.</p><p>SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for various cancer indications. Its lead product candidate is galinpepimut-S (GPS), currently in a pivotal Phase 3 REGAL trial for the treatment of acute myeloid leukemia, with final analysis approaching upon reaching 80 events.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜SELLAS Life Sciences Group Inc. Falls 8.06% in Regular Trading, Trading at $11.89</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜SELLAS Life Sciences Group Inc. Falls 8.06% in Regular Trading, Trading at $11.89\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-23 01:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 23, SELLAS Life Sciences Group Inc. fell 8.06% in regular trading, trading at $11.89 USD/share, with Turnover of $44.64 million.</p><p>Within the Biotechnology sector where SELLAS Life Sciences Group Inc. belongs, among individual stocks, Arrowhead Pharmaceuticals up 23.54%, Lakewood-Amedex Biotherapeutics up 70.7%, AbbVie down 0.8%, Ionis Pharmaceuticals down 0.42%, Regeneron Pharmaceuticals down 3.14%.</p><p>SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for various cancer indications. Its lead product candidate is galinpepimut-S (GPS), currently in a pivotal Phase 3 REGAL trial for the treatment of acute myeloid leukemia, with final analysis approaching upon reaching 80 events.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLS","symbol_name":"SELLAS Life Sciences Group Inc.","start_time":0,"source_url":"","article_id":"1110506485","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110506485","pubTimestamp":1784743101,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 23, SELLAS Life Sciences Group Inc. fell 8.06% in regular trading, trading at $11.89 USD/share, with Turnover of $44.64 million.Within the Biotechnology sector where SELLAS Life Sciences...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLS":"SELLAS Life Sciences Group Inc."},"translate_title":"走势警报|SELLAS Life Sciences Group Inc. 常规交易中下跌 8.06%，交易价格为 11.89 美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLS":1},"content_text":"On July 23, SELLAS Life Sciences Group Inc. fell 8.06% in regular trading, trading at $11.89 USD/share, with Turnover of $44.64 million.Within the Biotechnology sector where SELLAS Life Sciences Group Inc. belongs, among individual stocks, Arrowhead Pharmaceuticals up 23.54%, Lakewood-Amedex Biotherapeutics up 70.7%, AbbVie down 0.8%, Ionis Pharmaceuticals down 0.42%, Regeneron Pharmaceuticals down 3.14%.SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for various cancer indications. Its lead product candidate is galinpepimut-S (GPS), currently in a pivotal Phase 3 REGAL trial for the treatment of acute myeloid leukemia, with final analysis approaching upon reaching 80 events.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1110506485","isCrawlerRequest":true}